PL1934243T3 - Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych - Google Patents

Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych

Info

Publication number
PL1934243T3
PL1934243T3 PL06803140T PL06803140T PL1934243T3 PL 1934243 T3 PL1934243 T3 PL 1934243T3 PL 06803140 T PL06803140 T PL 06803140T PL 06803140 T PL06803140 T PL 06803140T PL 1934243 T3 PL1934243 T3 PL 1934243T3
Authority
PL
Poland
Prior art keywords
formula
compound
preparation
ring
closing metathesis
Prior art date
Application number
PL06803140T
Other languages
English (en)
Inventor
Chutian Shu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PL1934243T3 publication Critical patent/PL1934243T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL06803140T 2005-09-09 2006-09-08 Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych PL1934243T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71553405P 2005-09-09 2005-09-09
EP06803140A EP1934243B1 (en) 2005-09-09 2006-09-08 Ring-closing metathesis process for the preparation of macrocyclic peptides
PCT/US2006/034921 WO2007030656A1 (en) 2005-09-09 2006-09-08 Ring-closing metathesis process for the preparation of macrocyclic peptides

Publications (1)

Publication Number Publication Date
PL1934243T3 true PL1934243T3 (pl) 2011-10-31

Family

ID=37549189

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06803140T PL1934243T3 (pl) 2005-09-09 2006-09-08 Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych

Country Status (9)

Country Link
US (1) US7951773B2 (pl)
EP (1) EP1934243B1 (pl)
JP (1) JP5190364B2 (pl)
AT (1) ATE510846T1 (pl)
CA (1) CA2621360C (pl)
DK (1) DK1934243T3 (pl)
ES (1) ES2364426T3 (pl)
PL (1) PL1934243T3 (pl)
WO (1) WO2007030656A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US8193346B2 (en) * 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
JP5574982B2 (ja) 2008-02-04 2014-08-20 イデニク プハルマセウティカルス，インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
JP2011519943A (ja) * 2008-05-09 2011-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状分子の調製方法
BRPI0916609A2 (pt) * 2008-08-07 2015-08-04 Hoffmann La Roche Processo para a preparação de um macrociclo
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
BRPI0922912A8 (pt) 2008-12-10 2018-01-02 Achillion Pharmaceuticals Inc peptídeos de 4-amino-4-oxobutanoil como inibidores de replicação viral
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012327934B2 (en) * 2011-10-28 2017-06-01 Janssen Pharmaceuticals, Inc. Improved process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435
CA2887621A1 (en) 2012-10-08 2014-04-17 Abbvie Inc. Compounds useful for making hcv protease inhibitors
SG11201502802PA (en) 2012-10-19 2015-05-28 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
JP2016515139A (ja) 2013-03-14 2016-05-26 アキリオン ファーマシューティカルズ，インコーポレーテッド ソバプレビルの新規の製造方法
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
WO1999000397A1 (en) 1997-06-27 1999-01-07 Ciba Specialty Chemicals Holding Inc. Ruthenium and osmium catalysts
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004092203A2 (en) * 2003-04-10 2004-10-28 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic compounds
EP1615949A1 (en) * 2003-04-10 2006-01-18 Boehringer Ingelheim International GmbH Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction
DE602004031645D1 (de) 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus

Also Published As

Publication number Publication date
JP2009509933A (ja) 2009-03-12
ES2364426T3 (es) 2011-09-02
WO2007030656A8 (en) 2007-07-05
ATE510846T1 (de) 2011-06-15
JP5190364B2 (ja) 2013-04-24
EP1934243A1 (en) 2008-06-25
US20080242835A1 (en) 2008-10-02
US7951773B2 (en) 2011-05-31
DK1934243T3 (da) 2011-09-05
CA2621360C (en) 2013-12-24
CA2621360A1 (en) 2007-03-15
WO2007030656A1 (en) 2007-03-15
EP1934243B1 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
PL1934243T3 (pl) Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
WO2004092203A3 (en) Process for preparing macrocyclic compounds
WO2006096652A3 (en) Process for preparing macrocyclic compounds
IL178080A0 (en) Process for preparing macrocyclic compounds
PE20060607A1 (es) Derivados de indol tetraciclicos como agentes antivirales
DE602005013922D1 (de) Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
NZ588179A (en) Antiviral therapeutic agents comprising fused tricyclic compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety
WO2008057871A3 (en) Inhibitors of hepatitis c virus
WO2008057875A3 (en) Inhibitors of hepatitis c virus
NZ586232A (en) HCV protease inhibitors comprising a functionalised proline derivative
WO2008057873A3 (en) Inhibitors of hepatitis c virus
NZ595000A (en) Imidazo[4,5-c]pyridine derivative for treating viral infections
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
MY152153A (en) Macrocylic inhibitors of hepatitis c virus
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
PE20120993A1 (es) Derivados bifenilicos como antivirales
SG164376A1 (en) Hcv ns3 protease inhibitors
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
CA2616580A1 (en) Macrocyclic inhibitors of hepatitis c virus
TW200801044A (en) Macrocylic inhibitors of hepatitis C virus
Wang et al. N-Bromosuccinimide as an oxidant for the transition-metal-free synthesis of 2-aminobenzoxazoles from benzoxazoles and secondary amines
WO2008046860A3 (en) Bioavailable combinations for hcv treatment
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
CA2722867A1 (en) A method for preparing macrocycles
MX2012002958A (es) Compuestos antivirales heterociclicos.